Brief: Eagle Pharmaceuticals Announces Commercial Availability Of Vasopressin
18/01/2022 12:08
Jan 18 (Reuters) -
* EAGLE PHARMACEUTICALS ANNOUNCES COMMERCIAL AVAILABILITY OF
VASOPRESSIN
* EAGLE PHARMACEUTICALS INC - PRODUCT LAUNCH EXPECTED TO
DRIVE
SIGNIFICANT REVENUE GROWTH IN 2022
* EAGLE PHARMACEUTICALS INC - SHIPMENT OF VASOPRESSIN, A
GENERIC
ALTERNATIVE TO VASOSTRICT(®),( )COMMENCES TODAY
Source text for Eikon: ID:nBw3pFDq5a
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq